Unit of Infections and Cancer, Cancer Epidemiology Research Program, Catalan Institute of Oncology, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain; CIBER en Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain.
Eur J Cancer. 2013 Nov;49(16):3450-61. doi: 10.1016/j.ejca.2013.06.033. Epub 2013 Jul 22.
Human papillomavirus (HPV) contribution in vulvar intraepithelial lesions (VIN) and invasive vulvar cancer (IVC) is not clearly established. This study provides novel data on HPV markers in a large series of VIN and IVC lesions.
Histologically confirmed VIN and IVC from 39 countries were assembled at the Catalan Institute of Oncology (ICO). HPV-DNA detection was done by polymerase chain reaction using SPF-10 broad-spectrum primers and genotyping by reverse hybridisation line probe assay (LiPA25) (version 1). IVC cases were tested for p16(INK4a) by immunohistochemistry (CINtec histology kit, ROCHE). An IVC was considered HPV driven if both HPV-DNA and p16(INK4a) overexpression were observed simultaneously. Data analyses included algorithms allocating multiple infections to calculate type-specific contribution and logistic regression models to estimate adjusted prevalence (AP) and its 95% confidence intervals (CI).
Of 2296 cases, 587 were VIN and 1709 IVC. HPV-DNA was detected in 86.7% and 28.6% of the cases respectively. Amongst IVC cases, 25.1% were both HPV-DNA and p16(INK4a) positive. IVC cases were largely keratinising squamous cell carcinoma (KSCC) (N=1234). Overall prevalence of HPV related IVC cases was highest in younger women for any histological subtype. SCC with warty or basaloid features (SCC_WB) (N=326) were more likely to be HPV and p16(INK4a) positive (AP=69.5%, CI=63.6-74.8) versus KSCC (AP=11.5%, CI=9.7-13.5). HPV 16 was the commonest type (72.5%) followed by HPV 33 (6.5%) and HPV 18 (4.6%). Enrichment from VIN to IVC was significantly high for HPV 45 (8.5-fold).
Combined data from HPV-DNA and p16(INK4a) testing are likely to represent a closer estimate of the real fraction of IVC induced by HPV. Our results indicate that HPV contribution in invasive vulvar cancer has probably been overestimated. HPV 16 remains the major player worldwide.
人乳头瘤病毒(HPV)在外阴上皮内病变(VIN)和浸润性外阴癌(IVC)中的作用尚不清楚。本研究在大量 VIN 和 IVC 病变中提供了 HPV 标志物的新数据。
在加泰罗尼亚肿瘤研究所(ICO)收集了来自 39 个国家的经组织学证实的 VIN 和 IVC 病例。采用聚合酶链反应(PCR)用 SPF-10 广谱引物检测 HPV-DNA,并用反向杂交线探针分析(LiPA25)(版本 1)进行基因分型。IVC 病例用免疫组化(CINtec 组织学试剂盒,罗氏)检测 p16(INK4a)。如果同时观察到 HPV-DNA 和 p16(INK4a)过表达,则认为 IVC 为 HPV 驱动型。数据分析包括将多重感染分配给计算特定类型的贡献的算法,以及估计调整后的患病率(AP)及其 95%置信区间(CI)的逻辑回归模型。
2296 例中,587 例为 VIN,1709 例为 IVC。分别有 86.7%和 28.6%的病例检测到 HPV-DNA。在 IVC 病例中,25.1%的病例同时 HPV-DNA 和 p16(INK4a)阳性。IVC 病例主要为角化鳞状细胞癌(KSCC)(n=1234)。任何组织学亚型的年轻女性中 HPV 相关 IVC 病例的总体患病率最高。疣状或基底样特征 SCC(SCC_WB)(n=326)比 KSCC 更可能 HPV 和 p16(INK4a)阳性(AP=69.5%,CI=63.6-74.8)(AP=11.5%,CI=9.7-13.5)。最常见的 HPV 类型是 HPV 16(72.5%),其次是 HPV 33(6.5%)和 HPV 18(4.6%)。HPV 45 的富集程度从 VIN 到 IVC 显著升高(8.5 倍)。
HPV-DNA 和 p16(INK4a)检测的联合数据可能更接近 HPV 诱导 IVC 的真实比例。我们的结果表明,HPV 在浸润性外阴癌中的作用可能被高估。HPV 16 仍然是全球主要的致病因子。